Abstract:
Brazilian requirements for approval of biosimilars are aligned with a strict regulatory process and ensure the same high standards of quality, safety and efficacy as for originator biologicals.

Submitted: 29 September 2022; Revised: 26 January 2023; Accepted: 27 January 2023; Published online first:9 February 2023

In Brazil, a legal framework for approving follow-on biological products using a comparability pathway was established in 2010, via the Resolution of the Collegiate Board of Directors (RDC) biosimilars regulations, RDC 55/2010 [1, 2], by the National Health Surveillance Agency ( Agência Nacional de Vigilância Sanitária, ANVISA).

The Brazilian regulations (RDC 55/2010) are based on different regulations and guidelines from around the world, including the World Health Organization (WHO) Similar Biological Product Guidelines. The regulations follow the same scientific principles as the WHO guidelines but contain some differences due to the specific needs of Brazil [2].

This Resolution aims to establish the minimum requirements for the registration of new biological products and biological products in the country, aiming to guarantee the quality, safety and efficacy of these drugs. ANVISA does not have an approval pathway specific for biosimilars, and the Resolution provides two regulatory pathways; 1) comparability (follow-on biological) – a stepwise approach and 2) a stand-alone pathway (non-biosimilar), for non-originator biologicals [3].

ANVISA uses the terms of: (a) new biological product, for a new biological entity not yet registered; and (b) biological product, referring to the copy or follow-on products containing an active substance already registered [4].

In November 2022, ANVISA issued three new guidelines to regulate biologicals/biosimilars and radiopharmaceuticals [5].

Celltrion’s Remsima (infliximab) was the first biosimilar product approved in Brazil in 2015, by the comparative pathway and extrapolated a monoclonal antibody (mAb) indication for clinical indications outside those included in biopharmaceutical phase III studies (rheumatoid arthritis and ankylosing spondylitis).

By middle of May 2023, ANVISA has approved 52 follow-on biological/biosimilar products that act by replacing naturally produced insulin, promoting growth, encouraging the bone marrow to produce more white blood cells, blocking tumour necrosis factor-alpha (TNF- α) or vascular endothelial growth factor (VEGF), causing the death of B-lymphocytes, inhibiting the proliferation of human tumour cells that overexpress human epidermal growth factor receptor 2 (HER2), and acting as an anti-thrombotic, see Table 1.

Most follow-on biologicals/biosimilars approved in Brazil have all indications of the reference product. Brazilian regulations allow for extrapolation if comparability in terms of safety and efficacy between products is demonstrated, if the mechanism of action and receptors involved for the different indications are the same, and if the safety and immunogenicity profiles of the biological product are sufficiently characterized. In addition, the dosage form and route of administration of the follow-on biological/biosimilar product must be the same as the reference product.

The timeline in the Brazilian regulatory pathway is known to be newer when compared to other regulatory authorities. approval processes for follow-on biologicals/biosimilars in Brazil are following an evolutionary route. Brazilian requirements are much more aligned with a strict regulatory process and ensure the same high standards of quality, safety and efficacy for follow-on biologicals/biosimilars as for originator biologicals.

Biosimilars have the potential to provide savings and efficiencies for healthcare systems, which can free up resources for other important aspects of health care, changing the sad reality of lack of access to high-cost medications in low- and middle-income countries and opening a new era of broadening access [4-9]. Adopting a transparent approach in educating different stakeholders and including them in shaping guidelines could contribute to the acceptance of follow-on biologicals/biosimilars
in Brazil as has occurred in Europe [10].

Subscribe now to GaBI Journal to view full information of GaBI Journal published manuscripts.

This manuscript has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.